Mechanism of action
L‑valyl ester prodrug of acyclovir with improved oral bioavailability.
After conversion to acyclovir, viral thymidine kinase phosphorylates it to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and causes DNA chain termination in HSV‑1, HSV‑2 and VZV.